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Gastrointestinal stromal tumors (GIST) are rare soft
tissue sarcomas arising primarily from mesenchymal
tissue in the gastrointestinal tract and abdomen [1,2].
They account for only 1% of all tumors in the gas-
trointestinal system, but are the most common mes-
enchymal malignancies of the gastrointestinal tract
[3,4]. Because the tumor has a heterogeneous histo-
logic picture, which is composed mostly of spindle
cells but sometimes with epithelioid features, these
tumors were previously often classified as leiomyomas
and leiomyosarcomas, or even neurogenic tumors
[1,2,5]. Recently, the definition of GIST has evolved 
to be a mesenchymal tumor with overexpression of 
a transmembrane receptor tyrosine kinase stem cell
factor receptor (KIT, CD117) protein and it is now
known as a discrete neoplastic entity [6–8].
Surgery has so far been the only effective treat-
ment for GIST because the tumor has generally shown
resistance to chemotherapy and radiation therapy
[9,10]. Without effective management, patients with
metastatic and/or advanced disease have poor out-
comes [7]. Moreover, surgical intervention alone is
always inadequate, with many patients eventually
having a relapse after tumor resection [2]. Recently,
imatinib mesylate, a selective inhibitor that suppresses
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Gastrointestinal stromal tumors (GIST) are rare soft tissue sarcomas arising primarily from mes-
enchymal tissue in the gastrointestinal tract and abdomen. Since there is no effective treatment 
in the advanced stages, the outcome is poor in such patients. Recently, imatinib mesylate, a selec-
tive tyrosine kinase inhibitor, has shown a promising effect in GIST. Hence, we report our experi-
ence on the management of advanced GIST with imatinib therapy. A total of 14 patients were
enrolled in this study, including 10 males and four females (median age, 51 years). The results
showed that the small intestine was the most frequent site of primary lesion, while the liver was
the most frequently metastasized organ. Most of the patients experienced tolerable side effects
with imatinib therapy, including edema of periorbital area and/or legs and abdominal pain.
Only two mortalities were noted during follow-up. The patients clinically benefited from ima-
tinib therapy, with one patient having a complete response, three having a partial response, 
and seven having stable disease. The results demonstrate promising effects of imatinib in
advanced GIST.
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the activity of tyrosine kinase, showed a potential
effect on GIST with expression of CD117 [9,11]. This
launched a novel target therapy in GIST patients of
advanced status with promising results [12–14]. Here,
we report our experience of managing metastatic GIST
with imatinib therapy.
MATERIALS AND METHODS
Between 2001 and June 2005, a total of 14 GIST patients
with advanced/metastatic lesions were treated with
imatinib at Kaohsiung Medical University Hospital
and were enrolled in this study. All GISTs were diag-
nosed by histology and positive CD117 stain. The
advanced/metastatic lesions were confirmed by re-
biopsy and/or imaging study. Patients were prescribed
oral imatinib 400 mg once daily. Clinical presentation,
response, and side effects were reviewed from the
medical records.
Response to therapy was evaluated by follow-up
computed tomography (CT) or magnetic resonance
imaging, and a complete response (CR) was defined as
there being no evidence of disease for 1 month; a par-
tial response (PR) as a decrease in tumor size by ≥ 50%
in the sum of the products of the bi-perpendicular
diameters without new sites of disease; a progression
as a 25% increase in the sum of the products of the bi-
perpendicular diameters or any new sites of disease;
and stable disease (SD) as less than 50% response or
25% progression. Statistical analysis was performed
using SPSS version 11.5 (SPSS Inc., Chicago, IL, USA)
for Windows and the Kaplan–Meier method was used
for survival analysis.
RESULTS
Among the 14 patients, the small intestine was the
most frequent site of primary lesion, followed by the
stomach, colon, and omentum (Table). Eight patients
had metastatic lesions on diagnosis, while six patients
had metastatic lesions after initial surgical resection,
with an interval of 2–25 months. The liver was the most
frequently metastasized site, followed by the peri-
toneum (Table). All patients underwent surgical inter-
vention as the primary treatment. Even in patients
with initial metastasis, surgery for tumor removal
and diagnosis was also performed.
The patients took imatinib treatment at a dosage
of 400 mg daily for 2–44 months (median, 21 months).
However, one patient had poor drug compliance and
in another the dosage was increased to 600 mg daily
due to the absence of any response. Four patients had
also received other therapies for the metastatic lesions
before imatinib treatment, including three who had
received local radiotherapy without response. One
patient initially had a metastatic liver lesion and under-
went transarterial chemoembolization therapy before
surgical intervention. According to the National Cancer
Institute Common Toxicity Criteria, patients suffered
from tolerable side effects, including edema of the
periorbital area and/or legs, muscle cramping, and
gastrointestinal disturbance without any severe
(grade 3 or 4) side effects.
There were two deaths during treatment, one due
to internal tumor bleeding after imatinib and the
other due to pneumonia. The 2-year cumulative sur-
vival rate of patients during the follow-up period was
0.84 (Figure). Most of the patients (n = 7) showed SD,
with one CR, three PR, and one progressive disease.
DISCUSSION
GIST consistently shows a resistant character to chemo-
and radiotherapy with poor outcomes in patients
with unresectable and/or advanced status [2]. With
Table. Clinical characteristics of patients (n = 14)
Characteristic n
Median age (range), yr 51 (36–72)
Male/female 10/4
Primary lesions
Stomach 5
Small intestine 6
Colon 1
Omentum 2
Metastatic sites
Liver 8
Peritoneum 7
Spleen/pancreas invasion 1
Pleural invasion 1
Side effects of imatinib therapy
Edema of periorbital area and/or legs 9
Abdominal pain 8
Gastrointestinal disturbance 3
Imatinib in advanced GIST
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overexpression of the c-kit antigen in GIST, imatinib
therapy demonstrates a promising effect on these
patients [4,6]. It makes GIST a discrete neoplastic
entity not only in terms of pathologic diagnosis [7,8],
but also in management [9,11]. We present our expe-
rience of 14 GIST patients of advanced status and the
outcomes of imatinib therapy. Although there was a
male predominance in this study, the median age was
similar to other reports [9,12]. The most frequently
involved organ is the stomach, which accounts for
60–70% of patients. However, in our study, more than
half of the cases occurred in the small intestine. This
discrepancy might be due to the small number of
patients in our series.
Although there were two deaths in this study, the
other patients showed clinical benefits from imatinib
therapy. After administration of imatinib, most of the
patients (n = 11) had CR, PR, and/or SD, while only
one patient had progressive disease. Our data, simi-
lar to other reports [11–14], support the significant
benefit of imatinib therapy in patients with advanced
GIST. The side effects were also mild and tolerable
without significant hematologic toxicity in routine dos-
age and no intractable side effects. Compared to results
before the era of imatinib therapy when the 5-year
survival rate after surgical resection was only 28–43%
[2,15] and the median survival of recurrent GIST after
resection was 15 months [16], our results demonstrate
a promising development in the treatment of advanced
GIST. However, long-term follow-up is warranted for
a clear conclusion.
The most frequently metastasized site was the
liver, followed by the peritoneum, which was similar
to other reports [2]. Many patients suffered from
recurrent disease after initial resection of the tumor,
even after follow-up of 25 months. This stresses the
importance of regular follow-up even after total
tumor resection. Though the response was promising,
some of our patients still had advanced disease in the
diagnosis. Novel, multimodal protocols, including
neoadjuvant imatinib or resection of residual tumor
after imatinib, warrant further survey [14,16].
Furthermore, there are improvements in the man-
agement and diagnosis of  GISTs. Since a few GISTs
may not express CD117, making the diagnosis dif-
ficult, mutation survey, including KIT and platelet-
derived growth factor receptor α, is essential for
accurate diagnosis [8,17]. Mutation survey can also
help in the prediction of treatment response [17,18].
High-technique methods, such as multidetector CT,
are useful in detecting the exophytic component and
in evaluating the extent of disease [19]. These devel-
opments provide us with more information regard-
ing the treatment of GISTs.
In summary, we have reported our experience of
using imatinib for patients with advanced GIST. Most
of the patients benefited clinically from imatinib ther-
apy with tolerable side effects. However, long-term
follow-up is warranted for a clear conclusion.
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